Pharmaceutical Executive
May 19, 2015
Columns
35
5
Why executives should make the US R&D tax credit part of their planning discussions, by Chai Hoang and Chris Bard.
May 12, 2015
Features
35
5
Pharm Exec’s 9th annual Brand of the Year selection is Gilead Science’s back-to-back cures for HCV. We profile how both drugs reversed expectations around the listless product launch and revived industry reputation for startling breakthrough innovations.
May 11, 2015
Features
35
5
Gilead outlines its key access initiatives for its hepatitis C franchise.
May 08, 2015
Features
35
5
Tapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.
May 07, 2015
From the Editor
35
5
Pharm Exec's 2015 Brand of the Year Sovaldi and Harvoni are huge game-changers for Hepatitis C, but the big-picture impact will come down to how well the market aligns pricing, distribution, and access toward the broader goal of making sure that those patients who need the cure, get the cure.
May 02, 2015
Columns
35
5
Inspired by TV’s Mad Men, Julian Upton puts himself into a 1960 executive’s shoes to describe the “ethical pharma” industry of half a century ago
May 01, 2015
Columns
35
5
Insurers and payers demand lower prices-along with quality and innovation.
May 01, 2015
Columns
35
5
Tactics pharma leaders can implement to stem the continued global threat of counterfeit drugs.
May 01, 2015
Columns
35
5
Edging through the complex terrain that is health technology assessment in Europe
May 01, 2015
Special Sponsored Section
35
5
Once focused mainly on generic medicines, Korea’s pharma sector has leveraged significant new investments in R&D to transform itself into a true player in the global market-with aspirations as a future top-tier contributor to new medicines innovation.